JP6198013B2 - Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ - Google Patents

Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ Download PDF

Info

Publication number
JP6198013B2
JP6198013B2 JP2014533107A JP2014533107A JP6198013B2 JP 6198013 B2 JP6198013 B2 JP 6198013B2 JP 2014533107 A JP2014533107 A JP 2014533107A JP 2014533107 A JP2014533107 A JP 2014533107A JP 6198013 B2 JP6198013 B2 JP 6198013B2
Authority
JP
Japan
Prior art keywords
group
hypertension
disease
diabetes
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014533107A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2014034842A1 (ja
Inventor
直季 小島
直季 小島
ジェイ リチャード ローマン
ジェイ リチャード ローマン
宮田　則之
則之 宮田
禎介 高橋
禎介 高橋
英樹 友池
英樹 友池
卓也 武田
卓也 武田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of JPWO2014034842A1 publication Critical patent/JPWO2014034842A1/ja
Application granted granted Critical
Publication of JP6198013B2 publication Critical patent/JP6198013B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014533107A 2012-08-30 2013-08-30 Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ Active JP6198013B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695016P 2012-08-30 2012-08-30
US61/695016 2012-08-30
PCT/JP2013/073300 WO2014034842A1 (ja) 2012-08-30 2013-08-30 Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017107661A Division JP6358515B2 (ja) 2012-08-30 2017-05-31 Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ

Publications (2)

Publication Number Publication Date
JPWO2014034842A1 JPWO2014034842A1 (ja) 2016-08-08
JP6198013B2 true JP6198013B2 (ja) 2017-09-20

Family

ID=50183647

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014533107A Active JP6198013B2 (ja) 2012-08-30 2013-08-30 Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ
JP2017107661A Active JP6358515B2 (ja) 2012-08-30 2017-05-31 Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017107661A Active JP6358515B2 (ja) 2012-08-30 2017-05-31 Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ

Country Status (17)

Country Link
US (1) US9320727B2 (enExample)
EP (1) EP2891499A4 (enExample)
JP (2) JP6198013B2 (enExample)
KR (1) KR20150046125A (enExample)
CN (1) CN104780942A (enExample)
AU (1) AU2013309904A1 (enExample)
BR (1) BR112015004012A2 (enExample)
CA (1) CA2883118A1 (enExample)
HK (1) HK1208621A1 (enExample)
IN (1) IN2015DN01975A (enExample)
MX (1) MX2015002572A (enExample)
PH (1) PH12015500434B1 (enExample)
RU (1) RU2015110979A (enExample)
SG (1) SG11201501510SA (enExample)
TW (1) TW201414472A (enExample)
WO (1) WO2014034842A1 (enExample)
ZA (1) ZA201502009B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101943382B1 (ko) * 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
CN109806397A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Sglt2抑制剂与arb联合在制备治疗高血压等疾病的药物中的用途
KR102131359B1 (ko) * 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
JP7659783B2 (ja) 2019-09-13 2025-04-10 国立大学法人富山大学 急性心不全における体液貯留改善薬
JP2023523596A (ja) * 2020-04-22 2023-06-06 バイエル アクチェンゲゼルシャフト 心血管疾患および／または腎疾患を治療および／または予防するためのフィネレノンとｓｇｌｔ２阻害剤の組み合わせ
EP4197543A4 (en) * 2020-08-17 2024-05-15 Beijing Creatron Institute of Pharmaceutical Research Co., Ltd. COMPOSITION AND USE OF SGLT-2 INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS
JP7168133B1 (ja) * 2021-02-19 2022-11-09 大正製薬株式会社 経口フィルム製剤
EP4424309A4 (en) * 2021-10-27 2025-02-26 Meditake Co., Ltd. COMPOSITION WITH ANGIOTENSIN RECEPTOR BLOCKER AND SGLT2 INHIBITOR
CN120417911A (zh) * 2022-12-20 2025-08-01 斯法姆公司 包含钠-葡萄糖协同转运蛋白2抑制剂和血管紧张素ⅱ受体阻滞剂的用于预防或治疗心血管疾病的药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
PE20090185A1 (es) * 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
CN101754972A (zh) * 2007-05-18 2010-06-23 百时美施贵宝公司 Sglt2抑制剂的晶体结构及其制备方法
US20100167988A1 (en) 2008-10-22 2010-07-01 Auspex Pharmaceuticals, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2010119990A1 (en) * 2009-04-16 2010-10-21 Taisho Pharmaceutical Co., Ltd. Pharmaceutical compositions
JP2012528170A (ja) * 2009-05-27 2012-11-12 ブリストル−マイヤーズ スクイブ カンパニー 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法

Also Published As

Publication number Publication date
PH12015500434A1 (en) 2015-04-20
MX2015002572A (es) 2015-06-05
RU2015110979A (ru) 2016-10-20
HK1208621A1 (en) 2016-03-11
BR112015004012A2 (pt) 2017-07-04
US9320727B2 (en) 2016-04-26
WO2014034842A1 (ja) 2014-03-06
EP2891499A4 (en) 2016-02-24
JPWO2014034842A1 (ja) 2016-08-08
TW201414472A (zh) 2014-04-16
EP2891499A1 (en) 2015-07-08
JP6358515B2 (ja) 2018-07-18
AU2013309904A1 (en) 2015-03-19
ZA201502009B (en) 2016-07-27
JP2017186353A (ja) 2017-10-12
KR20150046125A (ko) 2015-04-29
US20150320721A1 (en) 2015-11-12
CN104780942A (zh) 2015-07-15
CA2883118A1 (en) 2014-03-06
PH12015500434B1 (en) 2022-04-22
IN2015DN01975A (enExample) 2015-08-14
SG11201501510SA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
JP6358515B2 (ja) Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ
EP2419097B1 (en) Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
EP4321157B1 (en) New use of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi)
US8765776B2 (en) Antihypertensive pharmaceutical composition
US20230201174A1 (en) Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
EP4197543A1 (en) Composition and use of sglt-2 inhibitor and angiotensin receptor blockers
WO2017006254A1 (en) Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
RU2718055C2 (ru) Производные 1,3-дигидроимидазол-2-тиона для применения в лечении легочной артериальной гипертензии и повреждения легкого
WO2004002473A1 (ja) 血糖コントロール用医薬組成物
AU780152B2 (en) Use of cortisol antagonists in the treatment for heat failure
EP2837380A1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
EP2517728B1 (en) Olmesartan medoxomil for preventing or treating angiogenic eye diseases
EP2568982B1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
TW200951117A (en) Combination of dronedarone with at least one diuretic, therapeutic application thereof
US10918612B2 (en) Combinations with 2-aminoethanesulfonic acid
JP4702054B2 (ja) 増強剤
CN107072977B (zh) Nep抑制剂药物组合及其应用
US20180311241A1 (en) Pharmaceutical synergistic combination
EP2387996A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation
EP2387997A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients who developed permanent atrial fibrillation throughout the period the dronedarone is administered
TW201103544A (en) Pharmaceutical composition and application thereof

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170531

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170726

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170808

R150 Certificate of patent or registration of utility model

Ref document number: 6198013

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250